Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations.

Because 8-aminoquinolines affect critical survival stages of Plasmodium parasites, treatment and control of malaria could be markedly improved by more widespread use of these drugs; however, hemolytic toxicity, which is widely prevalent in G6PD-deficient patients, severely constrains this use. Primaquine was approved more than 50 years ago after extensive clinical testing. Review of the mid-20th century literature in the light of present understanding of pharmacokinetics and metabolism suggests that manipulation of these factors might dissociate 8-aminoquinoline efficacy from toxicity and lead to an improved therapeutic index.

[1]  R. Price,et al.  Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Laura Dickinson,et al.  Grapefruit-Drug Interactions , 2010, Drugs.

[3]  Elizabeth Ashley,et al.  Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial , 2010, The Lancet. Infectious diseases.

[4]  B. Tekwani,et al.  Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. , 2009, Toxicology and applied pharmacology.

[5]  M. Marselos,et al.  Inhibition of rat hepatic CYP2E1 by quinacrine: molecular modeling investigation and effects on 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced mutagenicity , 2009, Archives of Toxicology.

[6]  Ernest Beutler,et al.  Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. , 2007, The American journal of tropical medicine and hygiene.

[7]  A. Magill,et al.  Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. , 2006, The American journal of tropical medicine and hygiene.

[8]  S. Prusiner,et al.  QUINACRINE IS MAINLY METABOLIZED TO MONO-DESETHYL QUINACRINE BY CYP3A4/5 AND ITS BRAIN ACCUMULATION IS LIMITED BY P-GLYCOPROTEIN , 2006, Drug Metabolism and Disposition.

[9]  K. Rieckmann,et al.  Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? , 2006, British journal of clinical pharmacology.

[10]  Anders Björkman,et al.  Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data , 2003, European Journal of Clinical Pharmacology.

[11]  P. Beaune,et al.  In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[12]  P. Rosenthal Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery. , 2002 .

[13]  S. Croft Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery. , 2001, Drug discovery today.

[14]  G. Edwards Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery , 2001 .

[15]  V. do Rosário,et al.  Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. , 1999, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[16]  Purnomo,et al.  Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. , 1995, The American journal of tropical medicine and hygiene.

[17]  N. White,et al.  Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. , 1993, British journal of clinical pharmacology.

[18]  H. Frischer,et al.  The conversion of primaquine into primaquine-aldehyde, primaquine-alcohol, and carboxyprimaquine, a major plasma metabolite. , 1991, The Journal of laboratory and clinical medicine.

[19]  S. Meshnick,et al.  In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei. , 1990, The American journal of tropical medicine and hygiene.

[20]  A. Tarlov,et al.  The hemolytic effect of primaquine. XV. Role of methemoglobin. , 1962, The Journal of laboratory and clinical medicine.

[21]  R. J. Dern,et al.  Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. , 1955, The Journal of laboratory and clinical medicine.

[22]  C. Clayman,et al.  3. TOXICITY OF PRIMAQUINE IN CAUCASIANS , 1952 .

[23]  E. Yount,et al.  Reactions observed during treatment with pentaquine, administered with quinacrine (atabrine) metachloridine (SN-11,437) and with sulfadiazine. , 1948, Journal. National Malaria Society.

[24]  Yount Eh,et al.  Reactions observed during treatment with pentaquine, administered with quinacrine (atabrine) metachloridine (SN-11,437) and with sulfadiazine. , 1948 .

[25]  C. Whorton,et al.  THE TOXICITY OF LARGE DOSES OF PENTAQUINE (SN-13,276), A NEW ANTIMALARIAL DRUG. , 1948, The Journal of clinical investigation.

[26]  D. Earle,et al.  STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. IX. EFFECT OF PAMAQUINE ON THE BLOOD CELLS OF MAN. , 1948, The Journal of clinical investigation.

[27]  C. Zubrod,et al.  STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. VIII. THE PHYSIOLOGICAL DISPOSITION OF PAMAQUINE. , 1948, The Journal of clinical investigation.

[28]  C. Whorton,et al.  PENTAQUINE (SN-13,276), A THERAPEUTIC AGENT EFFECTIVE IN REDUCING THE RELAPSE RATE IN VIV AX MALARIA. , 1948, The Journal of clinical investigation.

[29]  C. Whorton,et al.  Clinical Standardization of Pamaquin (Plasmochin) in Mosquito-Induced Vivax Malaria, Chesson Strain: A Preliminary Report1 , 1947 .

[30]  Organización Mundial de la Salud Guidelines for the treatment of malaria , 2010 .

[31]  Draft Guidance,et al.  Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , and Implications for Dosing and Labeling DRAFT GUIDANCE , 2006 .

[32]  P. Beaune,et al.  IN VITRO METABOLISM OF CHLOROQUINE : IDENTIFICATION OF CYP 2 C 8 , CYP 3 A 4 , AND CYP 2 D 6 AS THE MAIN ISOFORMS CATALYZING N-DESETHYLCHLOROQUINE FORMATION , 2003 .

[33]  C. Dutton,et al.  8-Aminoquinolines as anticoccidials--II. , 1997, Bioorganic & Medicinal Chemistry Letters.

[34]  R. J. Dern,et al.  The hemolytic effect of primaquine V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. , 1981, The Journal of laboratory and clinical medicine.

[35]  A. Lysenko Use of quinocide in treatment and prophylaxis of vivax malaria. , 1960, Bulletin of the World Health Organization.

[36]  Lysenko Ay Use of quinocide in treatment and prophylaxis of vivax malaria. , 1960 .

[37]  C. Clayman,et al.  Toxicity of primaquine in Caucasians. , 1952, Journal of the American Medical Association.

[38]  B. Craige,et al.  Pentaquine (SN-13,276) a therapeutic agent effective in reducing the relapse rate in vivax malaria. , 1948, The Journal of clinical investigation.

[39]  C. Zubrod,et al.  Studies on the chemotherapy of the human malarias; the physiological disposition of pamaquine. , 1948, Journal of Clinical Investigation.